Breadcrumb

[A18-68] Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)

Overview

Overview

Commission: Commission awarded on 2018-10-12 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 157 kB]Further documents
Note:

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-15.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-20] Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68
Status: Commission completed

[A13-20] Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-04-04 Extract of dossier assessment 157 kBPDFdownload file
2019-04-04 Dossier assessment (German version) 986 kBPDFdownload file

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-15.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision) [PDF, 157 kB]

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Ocriplasmin (Jetrea) for the treatment of vitreomacular traction

Federal Joint Committee (G-BA)

2019-04-04 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close